Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Change in Accured Expenses (2016 - 2026)

Oramed Pharmaceuticals filings provide 10 years of Change in Accured Expenses readings, the most recent being $1.2 million for Q4 2025.

  • Quarterly Change in Accured Expenses rose 177.39% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 67.94% year-over-year, with the annual reading at $1.1 million for FY2025, 67.94% down from the prior year.
  • Change in Accured Expenses hit $1.2 million in Q4 2025 for Oramed Pharmaceuticals, down from $3.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $3.2 million in Q3 2025 and bottomed at -$3.1 million in Q2 2025.
  • Average Change in Accured Expenses over 5 years is $308866.7, with a median of $1000.0 recorded in 2023.
  • The largest annual shift saw Change in Accured Expenses skyrocketed 42800.0% in 2024 before it tumbled 77275.0% in 2025.
  • Oramed Pharmaceuticals' Change in Accured Expenses stood at -$3000.0 in 2021, then soared by 166.67% to $2000.0 in 2022, then tumbled by 50.0% to $1000.0 in 2023, then skyrocketed by 42800.0% to $429000.0 in 2024, then surged by 177.39% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Change in Accured Expenses are $1.2 million (Q4 2025), $3.2 million (Q3 2025), and -$3.1 million (Q2 2025).